Skip to content

HPV Vaccine Hesitancy Among Indiana Youth With Cancer and Blood Diseases

HPV Vaccine Hesitancy Among Indiana Youth With Cancer and Blood Diseases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04667702
Enrollment
176
Registered
2020-12-16
Start date
2021-01-04
Completion date
2022-07-05
Last updated
2024-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Papilloma Virus Vaccine Hesitancy

Brief summary

For the identified groups of patients (survivors of childhood cancer and youth with sickle cell disease) the investigators want to better understand the barriers to, and facilitators of, HPV vaccination. Through HCP interviews the investigators will also assess both attitudinal and logistical obstacles to HPV vaccination. Some subspecialty HCPs may believe, for instance, that it is the primary care provider's responsibility to vaccinate or they may be unfamiliar with the requirement to enter vaccination data into CHIRP. Also, in some cases HPV vaccine may not be readily available in subspecialty clinic locations and/or subspecialty HCPs may not be Vaccines for Children (VFC) providers. Participants: the investigators will focus on two patient groups: survivors of childhood cancer, which includes children aged 9-21 years who have completed active therapy for cancer and are eligible for vaccination, and sickle cell disease, which includes children aged 9-21 years with a diagnosis of sickle cell disease. The investigators will recruit parents of children aged 9-21 years and older adolescents aged 18-21 years. For pediatric patients, the investigators selected a lower age of 9 years because HPV vaccine is licensed down to 9 years of age, and an upper limit of 21 years, as that is considered the upper bound of adolescence by the American Academy of Pediatrics. For patients 9-17 years of age, only parents will be interviewed by video or phone because parents are the vaccine decision-makers. For patients 18-21 years of age, the investigators will interview both young adults and their parents, because, while the young adult has legal decision-making capacity, in reality, the decision is frequently made jointly by the young adult and parent, and older adolescents are frequently unwilling to go against their parents' wishes. All research procedures will be conducted in English. Participants will be excluded if they have an intellectual disability or severe medical illness such that they are unable to consent or to understand the questions.

Interventions

BEHAVIORALInterviews

We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
9 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 9-21 years of age for patients with sickle cell disease or cancer. * Caregiver of patient with sickle cell disease or cancer. * Healthcare provider of patient with sickle cell disease or cancer.

Exclusion criteria

* n/a

Design outcomes

Primary

MeasureTime frameDescription
Vaccine Hesitancy 5 point Likert scale1 DayPatients will be scored using scale: 1=strongly disagree; 2=disagree; 3=neither agree nor disagree; 4=agree; and 5=strongly agree; lower scores mean less confidence/more hesitancy; higher scores mean more confidence/less hesitancy.
Hesitancy or Confidence of counseling or giving the HPV vaccine of health care providers1 DayInterview Results - no scale available. Themes and descriptive.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026